Procedure for Reporting of Protocol Deviations, Violations and Exception Requests

A. Background

The Human Research Protection Program recognizes that there will be situations where research activities deviate from the approved research protocol due to scheduling conflicts, patient non-compliance, emergency situations, or errors by research staff. This document strives to ensure accurate reporting to the IRB while making reporting as efficient as possible.

B. Definitions and Examples

A protocol deviation, violation, or participant non-compliance occurs when there is a departure from the approved research study protocol. In most cases, these are either 1) research activities that take place in a manner different from what the approved protocol states will occur, 2) failure to complete all research activities described in the approved protocol, or 3) research activities that are not included in the approved protocol.

Classification of a departure from the approved protocol as a deviation (minor departure) or a violation (major departure) will depend upon the extent of the departure as well as potential or actual consequences of the departure on patient risk, protocol integrity, IRB policy, or federal regulations.

1) A deviation is a departure from the protocol that has no potential substantive effect on the risks to participants or on the scientific integrity or the research plan or collected data. Willful or knowing misconduct on the part of the investigators cannot be classified as a deviation, regardless of the effect of the misconduct.

Examples of a deviation include the accidental failure of investigators to perform a scheduled physical or blood test that was included in the approved protocol, or a subject’s failure to correctly self-administer a study drug.

Deviations are generally noted after they occur, however in some cases they may be foreseen but unable to be avoided. For example, if a participant is unable to keep a scheduled appointment, they may call the investigators to inform them, but it is not within the control of the investigators that the appointment cannot be kept.

2) Deviations may be the result of participant non-compliance, which refers to departures from the IRB-approved protocol that have not been pre-approved and are not in the control of the researcher, but rather arise as the result of the participant’s actions. They may or may not have increased risk to the participant and/or result in a negative consequence. Only those instances of participant non-compliance that increase risk to the participant and/or result (or may result) in a negative consequence must be reported in a timely manner to the UT IRB. Other instances should be tracked and submitted to the IRB at the time of continuing review.
3) A principal investigator can request that the UT IRB (and sponsor if one exists) review and approve in writing a waiver for minor protocol departures prior to their occurrence by completing the **Single Subject Exception Request** form. If this written pre-approval occurs, these deviations do not need to be reported afterward to the UT IRB unless an unanticipated adverse event results from the variance. In such an instance, an adverse event report form must be filed along with the protocol/deviation form, and the UT IRB and all other required agency(ies) must be notified in compliance with government regulations.

4) A **violation** is a departure from the approved protocol, without previous IRB-approval, that has the potential to cause harm or increase risk to participants, has the potential to affect the scientific integrity of the research, and/or impacts a subject’s safety, rights, or welfare.

Examples of a violation include failure to properly obtain informed consent, or using an unapproved consent form, enrollment of ineligible subjects, or performing a research procedure not included in the approved protocol, or changing an approved study procedure such as using different dosing or infusion rates. In all cases, willful misconduct by investigators is classified as a protocol violation.

In some cases, a protocol violation may occur as a result of the investigator’s decision to deviate from the approved protocol in an attempt to avoid an increase in risk to the subject in an emergency situation. An example may include withholding the study drug in response to a serious adverse event that has occurred or the expectation that one may occur if the drug is administered as scheduled. In such emergency situations, the departure from protocol may proceed and the IRB must be notified.

**C. The Procedure for Reporting Protocol Deviations, Violations and Exception Requests**

To determine when a departure from an approved protocol should be reported to the IRB and which form should be used, please see the following:

1) If the decision to depart from the approved protocol is under the control of the Principal Investigator (PI) (for example, the PI decides to delay treatment due to lab results or other findings), the PI should inform the IRB as soon as possible by submitting a Single Subject Exception form to be reviewed and approved prior to deviating from the protocol, unless the decision is made to avoid an increase in risk to the subject, such as a negative impact to the subject’s rights, safety or welfare. In such a case, the deviation/violation should be reported to the IRB within 10 working days after the deviation occurs using the Protocol Deviation/Violation form.

2) If the decision to depart from the approved protocol is not under the control of the PI (for example, if there is an unavoidable scheduling conflict, the subject fails to complete all necessary steps/tasks required of them, or a member of the research staff makes an error), the PI should submit a Protocol Deviation/Violation form to the IRB within 10 working days **only** in the event that the departure from the protocol will or could possibly adversely affect the subject’s rights, safety or welfare or if the departure has or will impact the science of the study. If neither of these impacts will occur, the departure should be tracked and reported at the time of continuing review.

The PI (and sponsor, if applicable) should review protocol deviations/violations to determine whether a protocol amendment is necessary to reduce the number of deviations. Such amendments might
include adding a plus/minus window to study days to allow for more flexible scheduling, so long as
subject safety would not be adversely affected.